These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36799420)

  • 21. Recent Progress and Perspectives in Sodium-Glucose Co-transporter 1/2 Inhibitors.
    Demirkiran C; Demiryürek S; Demiryürek AT
    Mini Rev Med Chem; 2024 Aug; ():. PubMed ID: 39162279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
    Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
    J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
    Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
    Tanashat M; Manasrah A; Abouzid M
    Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature.
    Abdelmasih R; Abdelmaseih R; Thakker R; Faluk M; Ali A; Alsamman MM; Hasan SM
    Cardiol Res; 2021 Aug; 12(4):210-218. PubMed ID: 34349861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure.
    Choday S; Ravi N; Parisapogu A; Ojinna BT; Sherpa ML
    Cureus; 2023 Feb; 15(2):e34687. PubMed ID: 36909046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA; Pinner NA
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.
    Oh J; Lee SH; Lee CJ; Kang SM
    Korean Circ J; 2021 May; 51(5):399-408. PubMed ID: 33975387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
    JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
    Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.
    Kubota Y; Shimizu W
    JACC Asia; 2022 Jun; 2(3):287-293. PubMed ID: 36338417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review.
    Keller DM; Ahmed N; Tariq H; Walgamage M; Walgamage T; Mohammed A; Chou JT; Kałużna-Oleksy M; Lesiak M; Straburzyńska-Migaj E
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
    Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
    EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier.
    Aguiar-Neves I; Santos-Ferreira D; Fontes-Carvalho R
    Rev Cardiovasc Med; 2023 Jan; 24(1):1. PubMed ID: 39076855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction.
    De Marzo V; Savarese G; Porto I; Metra M; Ameri P
    J Cardiovasc Med (Hagerstown); 2023 Aug; 24(8):537-543. PubMed ID: 37409599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
    Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.